By Associate Professor Hao-Wen Sim

Journal articles

Natori A; Sim H-W; Chan BA; Sun P; Moignard S; Yokom D; Lim CH; Jiang M; Ma LX; Chen EX; Liu G; Knox JJ; Darling GE; Yeung JC-W; Wong R; Hafezi-Bakhtiari S; Conner J; Rogalla P; Jang RW-J; Elimova E, 2018, 'Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, 36, pp. 122 - 122, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.122

Yokom D; Natori A; Sim H-W; Chan BA; Moignard S; Sun P; Lim CH; Jiang DM; Ma LX; Darling GE; Swallow CJ; Brierley JD; Wong R; Liu G; Chen EX; Knox JJ; Alibhai SMH; Jang RW-J; Elimova E, 2018, 'Management of metastatic gastric and esophageal cancer in older adults.', Journal of Clinical Oncology, 36, pp. 163 - 163, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.163

Lim CH; Yokom D; Jiang DM; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Moignard S; Knox JJ; Chen EX; Liu G; Swallow CJ; Darling GE; Brar SS; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2018, 'Outcomes for advanced HER2-positive gastroesophageal cancer by anatomical location: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, 36, pp. 131 - 131, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.131

Jiang DM; Lim CH; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Chen EX; Liu G; Knox JJ; Swallow CJ; Darling GE; Brar SS; Hafezi-Bakhtiari S; Conner J; Jang RW-J; Elimova E, 2018, 'Patterns of recurrence and outcomes after curative resection of locally advanced HER2-positive gastroesophageal cancer (HPGEC).', Journal of Clinical Oncology, 36, pp. 147 - 147, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.147

Ma LX; Lim CH; Sun P; Jiang M; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Le LW; Chen EX; Liu G; Swallow CJ; Darling GE; Kongkham PN; Shultz D; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2018, 'Relationship between human epidermal growth factor receptor 2 (HER2) status and central nervous system metastases in gastroesophageal cancer.', Journal of Clinical Oncology, 36, pp. 145 - 145, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.145

Chan BA; Sim H-W; Natori A; Moignard S; Yokom D; Lim CH; Jiang DM; Chen EX; Knox JJ; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J; Hafezi-Bakhtiari S; Elimova E; Jang RW-J, 2018, 'Survival outcomes for de novo versus relapsed stage IV gastric and gastroesophageal junction (GEJ) adenocarcinoma.', Journal of Clinical Oncology, 36, pp. 148 - 148, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.148

O'Kane GM; Fraser A; Moignard S; Dodd A; Creighton S; Sim H-W; Aung KL; Borgida A; Gallinger S; Knox JJ, 2018, 'The impact of lung and bone metastases on prognosis in advanced PDAC.', Journal of Clinical Oncology, 36, pp. 494 - 494, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.494

Sim HW; Morgan ER; Mason WP, 2018, 'Contemporary management of high-grade gliomas', CNS Oncology, 7, pp. 51 - 65, http://dx.doi.org/10.2217/cns-2017-0026

Stukalin I; Connor Wells J; Fraccon A; Pasini F; Porta C; Lalani AKA; Srinivas S; Alex Bowman I; Brugarolas J; Lee JL; Donskov F; Beuselinck B; Bamias A; Rini BI; Sim HW; Agarwal N; Rha SY; Kanesvaran R; Choueiri TK; Heng DYC, 2018, 'Fourth-line therapy in metastatic renal cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC)', Kidney Cancer, 2, pp. 31 - 36, http://dx.doi.org/10.3233/KCA-170020

Sim HW; Knox J, 2018, 'Hepatocellular carcinoma in the era of immunotherapy', Current Problems in Cancer, 42, pp. 40 - 48, http://dx.doi.org/10.1016/j.currproblcancer.2017.10.007

Lewin J; Garg S; Lau BY; Dickson BC; Traub F; Gokgoz N; Griffin AM; Ferguson PC; Andrulis IL; Sim HW; Kamel-Reid S; Stockley TL; Siu LL; Wunder JS; Razak ARA, 2018, 'Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma', International Journal of Cancer, 142, pp. 57 - 65, http://dx.doi.org/10.1002/ijc.31039

Sim H-W; Stundzia A; Pierre S; Metser U; O’Malley M; Elimova E; Sridhar SS; Hansen A, 2018, '896P Predictive radiomics signature for treatment response to nivolumab in patients (pts) with advanced renal cell carcinoma (RCC)', Annals of Oncology, 29, pp. viii318, http://dx.doi.org/10.1093/annonc/mdy283.105

Sim HW; Knox J; Dawson LA, 2017, 'An Update on Randomized Clinical Trials in Hepatocellular Carcinoma', Surgical Oncology Clinics of North America, 26, pp. 647 - 666, http://dx.doi.org/10.1016/j.soc.2017.05.006

Jiang DM; Sim H-W; Siu LL; Shapiro JD; Liu G; Price TJ; Jonker DJ; Karapetis CS; Strickland A; Zhang W; Jeffery M; Tu D; Ng S; Sabesan SS; Shannon J; Townsend AR; Morgen E; Xu W; O'Callaghan CJ; Chen EX, 2017, 'Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).', Journal of Clinical Oncology, 35, pp. 3600 - 3600, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.3600

Yip S; Wells C; Moreira RB; Wong A; Srinivas S; Beuselinck B; Porta C; Sim H-W; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood L; Canil CM; Kapoor A; Fu SYF; Choueiri TK; Heng DYC, 2017, 'Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).', Journal of Clinical Oncology, 35, pp. 4580 - 4580, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4580

Bosse D; Xie W; Wells C; Lalani A-KA; Donskov F; Bent A; Sim H-W; Beuselinck B; Bamias A; Porta C; Vaishampayan UN; Pal SK; Agarwal N; Srinivas S; Rini BI; Alva AS; Wood L; Kapoor A; Choueiri TK; Heng DYC, 2017, 'Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).', Journal of Clinical Oncology, 35, pp. e16065 - e16065, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e16065

Sim H-W; Nejad R; Zhang W; Mason WP; Bernstein M; Aldape K; Zadeh G; Chen EX, 2017, 'Comparison of 2-hydroxyglutarate (2HG) levels in tissue and serum of isocitrate dehydrogenase (IDH)-mutated (MUT) versus wild-type (WT) gliomas.', Journal of Clinical Oncology, 35, pp. 2037 - 2037, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.2037

Sim H-W; Chan BA; Natori A; Lim CH; Jiang DM; Moignard S; Chen EX; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Knox JJ; Jang RW-J; Elimova E, 2017, 'Comparison of chemoradiotherapy (CRT) using carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or gastroesophageal junctional (GEJ) cancer.', Journal of Clinical Oncology, 35, pp. 4053 - 4053, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4053

Samawi H; Sim H-W; Chan KK; Alghamdi MA; Lee-Ying RM; Knox JJ; Gill P; Romagnino A; Batuyong E; Ko Y-J; Cheung WY; Tam VC, 2017, 'Comparison of prognostic models for hepatocellular carcinoma (HCC) in patients treated with the sorafenib: Results from a Canadian multi-center HCC database.', Journal of Clinical Oncology, 35, pp. e15653 - e15653, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e15653

Alghamdi MA; Lee-Ying R; Sim H-W; Samawi H; Knox JJ; Romagnino A; Ko Y-J; Chan KK; Swiha M; Batuyong E; Cheung WY; Tam VC, 2017, 'Effect of sorafenib (S) starting dose and dose intensity on survival in patients with hepatocellular carcinoma (HCC): Results from a Canadian multicenter HCC database.', Journal of Clinical Oncology, 35, pp. 4084 - 4084, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4084

Basappa NS; Lalani A-KA; Kalirai A; Li H; Wood L; Kollmannsberger CK; Sim H-W; Kapoor A; Hotte SJ; Czaykowski P; Canil CM; Reaume MN; Bjarnason GA; Vanhuyse M; Soulieres D; North SA; Heng DYC, 2017, 'Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).', Journal of Clinical Oncology, 35, pp. e16078 - e16078, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e16078

Natori A; Chan BA; Sim H-W; Ma LX; Yokom D; Chen EX; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox JJ; Elimova E; Jang RW-J, 2017, 'Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, 35, pp. 10037 - 10037, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.10037

Stukalin I; Wells C; Fraccon AP; Pasini F; Porta C; Moreira RB; Srinivas S; Bowman IA; Brugarolas J; Lee J-L; Donskov F; Beuselinck B; Bamias A; Rini BI; Sim H-W; Agarwal N; Rha SY; Kanesvaran R; Choueiri TK; Heng DYC, 2017, 'Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).', Journal of Clinical Oncology, 35, pp. 498 - 498, http://dx.doi.org/10.1200/jco.2017.35.6_suppl.498

Basappa NS; Lalani A-KA; Li H; Kalirai A; Wood L; Kollmannsberger CK; Sim H-W; Kapoor A; Hotte SJ; Czaykowski P; Canil CM; Reaume MN; Bjarnason GA; Vanhuyse M; Soulieres D; Levesque E; North SA; Heng DYC, 2017, 'Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).', Journal of Clinical Oncology, 35, pp. 468 - 468, http://dx.doi.org/10.1200/jco.2017.35.6_suppl.468

Yip S; Wells C; Moreira RB; Wong A; Srinivas S; Beuselinck B; Porta C; Sim H-W; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood L; Soulieres D; Canil CM; Kapoor A; Fu SYF; Choueiri TK; Heng DYC, 2017, 'Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC.', Journal of Clinical Oncology, 35, pp. 492 - 492, http://dx.doi.org/10.1200/jco.2017.35.6_suppl.492

Jiang DM; Sim H-W; Siu LL; Shapiro JD; Liu G; Price TJ; Jonker DJ; Karapetis CS; Strickland A; Zhang W; Jeffery M; Tu D; Ng S; Sabesan SS; Shannon J; Townsend AR; Morgen E; Xu W; O'Callaghan CJ; Chen EX, 2017, 'Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).', Journal of Clinical Oncology, 35, pp. 699 - 699, http://dx.doi.org/10.1200/jco.2017.35.4_suppl.699

Sim H-W; Chan B; Natori A; Lim CH; Jiang DM; Chen EX; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox JJ; Jang RW-J; Elimova E, 2017, 'Comparison of chemoradiotherapy (CRT) with carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or junctional cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, 35, pp. 126 - 126, http://dx.doi.org/10.1200/jco.2017.35.4_suppl.126

Natori A; Chan B; Sim H-W; Chen EX; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J-HJ; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox JJ; Elimova E; Jang RW-J, 2017, 'Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, 35, pp. 189 - 189, http://dx.doi.org/10.1200/jco.2017.35.4_suppl.189

Lalani AKA; Li H; Heng DYC; Wood L; Kalirai A; Bjarnason GA; Sim HW; Kollmannsberger CK; Kapoor A; Hotte SJ; Vanhuyse M; Czaykowski P; Reaume MN; Soulieres D; Venner P; North S; Basappa NS, 2017, 'First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience', Journal of the Canadian Urological Association, 11, pp. 112 - 117, http://dx.doi.org/10.5489/cuaj.4398

Yip SM; Ruiz Morales JM; Donskov F; Fraccon A; Basso U; Rini BI; Lee JL; Bjarnason GA; Sim HW; Beuselinck B; Kanesvaran R; Brugarolas J; Koutsoukos K; Fu SYF; Yuasa T; Davis I; Alva A; Kollmannsberger C; Choueiri TK; Heng DYC, 2017, 'Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)', Kidney Cancer, 1, pp. 41 - 47, http://dx.doi.org/10.3233/KCA-160002

Donskov F; Xie W; Wells JC; Fraccon AP; Pasini F; Porta C; Stukalin I; Lee JL; Bamias A; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim H-W; Agarwal N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC, 2017, '883P Synchronous vs metachronous metastatic disease: Impact of time to metastasis on outcome in metastatic renal cell carcinoma patients treated with targeted therapy', Annals of Oncology, 28, pp. v311 - v312, http://dx.doi.org/10.1093/annonc/mdx371.037

Nejad R; Sim H; Aldape K; Mason W; Bernstein M; Gentili F; Kalia S; Tung T; Chen E; Zadeh G, 2017, 'P10.21 2-hydroxyglutarate as a biomarker for IDH mutation in low grade gliomas', Neuro-Oncology, 19, pp. iii89 - iii90, http://dx.doi.org/10.1093/neuonc/nox036.339

Chan BA; Sim H-W; Ravikumar A; Bailey D; Chan D; Lawrence B; McEwan A; Pavlakis N; Segelov E; Singh S; Roach P; Wyld D, 2016, '417P Availability and Utility of Functional Imaging (FI) and Peptide Receptor Radionuclide Therapy (PRRT) in the CommNETS Collaboration (Australia, Canada and New Zealand)', Annals of Oncology, 27, http://dx.doi.org/10.1093/annonc/mdw590.003

Chan B; Sim H-W; Zimmermann C; Krzyzanowska MK, 2016, 'Systematic review of interventions to facilitate advance care planning (ACP) in cancer patients.', Journal of Clinical Oncology, 34, pp. 21 - 21, http://dx.doi.org/10.1200/jco.2016.34.26_suppl.21

Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DYC, 2016, 'First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium', European Journal of Cancer, 65, pp. 102 - 108, http://dx.doi.org/10.1016/j.ejca.2016.06.016

Sim H-W; Zadeh G; Mason WP; Aldape K; Bernstein M; Gentili F; Hodaie M; Kalia S; Kongkham PN; Zhang W; Tung T; Chen EX, 2016, 'Comparison of oncometabolite 2-hydroxyglutarate (2HG) levels in mutant isocitrate dehydrogenase (IDH) versus wild-type (WT) glioma tissues.', Journal of Clinical Oncology, 34, pp. 2028 - 2028, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.2028

Ruiz Morales JM; Swierkowski M; Wells C; Fraccon AP; La Russa F; Donskov F; Bjarnason GA; Lee J-L; Sim H-W; Beuselinck B; Wood L; Yuasa T; Pezaro CJ; Rini BI; Szczylik C; Choueiri TK; Heng DYC, 2016, 'First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).', Journal of Clinical Oncology, 34, pp. 4510 - 4510, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.4510

Li H; Kroeger N; de Velasco G; Donskov F; Sim H-W; Wells C; Stukalin I; Agarwal N; Parekh HD; Rini BI; Knox JJ; Pantuck AJ; Choueiri TK; Heng DYC, 2016, 'The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy.', Journal of Clinical Oncology, 34, pp. 552 - 552, http://dx.doi.org/10.1200/jco.2016.34.2_suppl.552

Chan BA; Sim H-W; Ravikumar A; Bailey D; Chan D; Lawrence B; McEwan A; Pavlakis N; Segelov E; Singh S; Roach P; Wyld D, 2016, '417P Availability and Utility of Functional Imaging (FI) and Peptide Receptor Radionuclide Therapy (PRRT) in the CommNETS Collaboration (Australia, Canada and New Zealand)', Annals of Oncology, 27, pp. ix130 - ix130, http://dx.doi.org/10.1016/s0923-7534(21)00575-5

Kröger N; Li H; De Velasco G; Donskov F; Sim H-W; Wells C; Stukalin I; Agarwal N; Parekh H; Rini B; Knox J; Pantuck A; Choueiri T; Heng D, 2016, '756 Active smoking is an adverse prognostic factor for survival outcome in metastatic renal cell carcinoma patients treated with targeted therapies', European Urology Supplements, 15, pp. e756 - e756, http://dx.doi.org/10.1016/s1569-9056(16)60758-3

Lalani A-K; Li H; Heng D; Wood L; Kalirai A; Bjarnason G; Sim H-W; Kollmannsberger CK; Kapoor A; Hotte SJ; Vanhuyse M; Czaykowski P; Reaume MN; Soulieres D; Venner P; North S; Basappa N, 2016, '819P Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience', Annals of Oncology, 27, pp. vi285, http://dx.doi.org/10.1093/annonc/mdw373.46

Tan LTY; Lewin JH; Urban D; Sim H-W; Hicks RJ; Byron K; Guccione L; Schaef E; Luen SJ; Tothill R; Schofield P; Bowtell D; Mileshkin LR, 2015, 'Retrospective review of the impact of a dedicated Cancer of Unknown Primary (CUP) clinic.', Journal of Clinical Oncology, 33, pp. e17680 - e17680, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.e17680

Sim HW; Morris PG; Patil S; Khasraw M, 2014, 'Brain metastases in breast cancer', Expert Review of Anticancer Therapy, 14, pp. 173 - 183, http://dx.doi.org/10.1586/14737140.2014.863468

Conference Papers

Bridgewater JA; Gardini AC; Wilmink H; Mercade TM; Sim H-W; Verslype C; Roderburg C; Touchefeu Y; McDermott RS; Kordes M; Lee C-K; Vogel A; Kzhdryan HGK; Vidra RA; Rumpold H; Sullivan A; Gharbi H; Minguez VM; Rober R; Rimassa L, 2025, 'Preliminary efficacy outcomes of ivosidenib in patients with IDH1-mutated cholangiocarcinoma (mIDH1 CCA): Initial results from the phase IIIb ProvIDHe study', in ANNALS OF ONCOLOGY, ELSEVIER, SPAIN, Barcelona, presented at ESMO Gastrointestinal Cancers Congress, SPAIN, Barcelona, 02 July 2025 - 05 July 2025, http://dx.doi.org/10.1016/].annonc.2025.05.277

Price T; Sim H-W; Eastgate M; Mclachlan S-A; Dean A; George D; Weeratunge R; Zhang Y; Oo MM, 2025, 'Australian patients with IDH₁ mutatedcholangiocarcinoma treated with ivosidenib: initial resultsfrom the phase 3b ProvIDHe study', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY

Mason SRE; Chung S; Satgunaseelan L; McCool C; Juan BP-S; Gupta S; Zaman A; Day BW; Dear R; Sim H-W; Holst J; Chaffer CL, 2024, 'EXTH-26. EXPLORING THE ROLE OF ANDROGEN RECEPTOR SIGNALING IN GLIOBLASTOMA IN AN ORTHOTOPIC ANIMAL MODEL', in Neuro-Oncology, Oxford University Press (OUP), pp. viii242 - viii242, http://dx.doi.org/10.1093/neuonc/noae165.0957

Pitiyarachchi O; Sim H-W, 2024, '256P PIK3CA mutations in pancreatic ductal adenocarcinoma (PDAC)', in Annals of Oncology, Elsevier, pp. s1499, http://dx.doi.org/10.1016/j.annonc.2024.10.274

Haggstrom L; Chan W; Nagrial A; Chantrill L; Yip D; Sim H-W; Chin V, 2024, 'Chemotherapy and Radiotherapy for Advanced Pancreatic Cancer: A Cochrane Systematic Review and Meta-Analysis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 39 - 40

McNamee N; Lin F; Sim H-W; Napier C; Thomas D; Simes J; Thavaneswaran S, 2023, 'EXPLORING THE PROGNOSTIC IMPLICATIONS OF MOLECULAR ALTERATIONS IN ASTROCYTOMAS USING COMPREHENSIVE GENOMIC PROFILING (CGP)', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CANADA, Vancouver, presented at 28th Annual Scientific Meeting of the Society-for-Neuro-Oncology (SNO), CANADA, Vancouver, 15 November 2023 - 19 November 2023

Mason S; Chung S; Juan BPS; Sim H-W; Dear R; Day B; Holst J; Chaffer C, 2023, 'TARGETING ANDROGEN SIGNALING IN GLIOBLASTOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CANADA, Vancouver, presented at 28th Annual Scientific Meeting of the Society-for-Neuro-Oncology (SNO), CANADA, Vancouver, 15 November 2023 - 19 November 2023

Back to profile page